About Biomyx Technology
Biomyx Technology is a company based in San Diego (United States) founded in 2002. It operates as a B2B and Direct Sales. Biomyx Technology offers products and services including DsiRNA™, ProLink™, Stimulight™ Reporters, Stem Cell Research Reagents, and ProteGene™. Biomyx Technology operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter San Diego, United States
- SectorsHealthcare
- Email••••••••
- Website biomyx.net
- Legal Name Biomyx, Inc
Products & Services of Biomyx Technology
Biomyx Technology offers a comprehensive portfolio of products and services, including DsiRNA™, ProLink™, Stimulight™ Reporters, Stem Cell Research Reagents, and ProteGene™.
Cost-effective tool for specific gene knock-down in mammalian cells.
Technology for site-specific protein and peptide labeling with known stoichiometry.
Enables creation of stable cell lines for in vivo pathway studies.
Novel tools for advancing stem cell research applications.
Expression-ready reagents for gene-specific applications.
Competitors of Biomyx Technology
Biomyx Technology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Biomyx Technology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biomyx Technology
Websites that share an audience with Biomyx Technology (biomyx.net).
Websites whose visitors overlap most with Biomyx Technology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kreatech.com | 100% | – | – | View details | |
| qualitybiological.com | 100% | 5.9K | #3,332,912 | View details | |
| teknova.com | 90% | 36.5K | #825,433 | View details |
Similar companies to Biomyx Technology
10 companies that operate in the same segment as Biomyx Technology (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Biomyx Technology
Biomyx Technology was founded in 2002.
Biomyx Technology is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Biomyx focuses on creating high-quality technologies to study gene functions and enhance biomedical research. The company offers products like siRNA for gene expression knock-down and tools for protein ligation, along with services in molecular biology. Based in San Diego, USA, it serves researchers and institutions with easy-to-use solutions for functional genomics and stem cell studies, emphasizing cost-effectiveness and convenience.
Biomyx Technology's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Biomyx Technology offers DsiRNA™, ProLink™, Stimulight™ Reporters, Stem Cell Research Reagents, and ProteGene™.
Biomyx Technology operates through Biomyx, Inc.